CCR5 targeting therapeutic - Collaborations Pharmaceuticals
Latest Information Update: 26 Apr 2024
At a glance
- Originator Collaborations Pharmaceuticals
- Class Antivirals
- Mechanism of Action CCR5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV-1 infections
Most Recent Events
- 18 Apr 2024 Collaborations Pharmaceuticals files patent for CCR5 targeting therapeutic prior to April 2024 (Collaborations Pharmaceuticals pipeline, April 2024)
- 18 Apr 2024 Preclinical trials in HIV-1 infections in USA (unspecified route) before April 2024 (Collaborations Pharmaceuticals pipeline, April 2024)